patients 47 patients treated with calcitriol versus 44 patients treated with maxacalcitol for 12 months
There were no significant differences between the two groups in serum iPTH
No significant differences between the two groups in phosphorus concentration. Serum calcium was significantly higher in the maxacalcitol versus calcitriol group during early treatment, but not at the end of treatment
Uremic (5/6 NX) rats fed a high-phosphate diet and treated by a direct injection of maxacalcitol-OCT (DI-OCT) or vehicle (DI-vehicle)
DI-OCT decreased PTH levels with a significant difference DI-OCT versus DI-vehicle. Upregulations of both VDR and CaSR after DI-OCT were observed versus DI-vehicle-treated rats.
Serum calcium and phosphorus levels did not changed markedly in both groups
nondiabetic hemodialysis patients with PTH levels greater than 300 pg/mL treated with either maxacalcitol () or calcitriol () for 24 weeks.
Both treatments decreased plasma intact PTH levels () and increased serum Ca levels (). PTH levels were significantly lower in the maxacalcitol group after 24 weeks ().
Serum phosphate was significantly greater in the calcitriol group ()
Nondiabetic dialysis patients () with iPTH levels >300 pg/mL were treated with i.v. maxacalcitol injected 3/week for 48 weeks.
96 patients were successfully treated (iPTH levels < 300 pg/ml within 48 weeks). Pretreatment PTH and Ca levels were lower in patients successfully treated with maxacalcitol.
Serum phosphorus levels did not significantly increase. Phosphorus levels were not predictive of the response to treatment with maxacalcitol.
